Lantern Pharma Inc. (NASDAQ ... with the potential to advance to Phase 1b or 2 by early to mid 2025. LP-284 has shown nanomolar potency across multiple published in vitro and in vivo studies, ...
Lantern Pharma cautions that these forward-looking statements are subject to risks ... We recorded a net loss of approximately $4.5 million for the third quarter of 2024 or $0.42 per share compared to ...
Holiday decorations including light displays, Christmas trees and candles on a mantle or in a jack-o-lantern can start a fire if left unattended. "We recommend that you use LED lights or battery ...